In the news at the end of last week, the NYT reported that a Lilly executive had encouraged the promotion of its schizophrenia drug Zyprexa for a use not approved by federal regulators.
The report said John Lechleiter, set to become chief executive in April, wrote an e-mail in 2003 discussing the use of Zyprexa by children and teenagers, although it is only approved for adults with schizophrenia or bipolar disorder.
The state of Connecticut has sued Lilly accusing it of illegally marketing and concealing its serious side effects. It faces similar accusations in Alaska as well.
For more, go here.
